Condition (MeSH)
Proximal Femoral Fractures
ClinicalTrials.gov lists 34 trials for Proximal Femoral Fractures or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
34 of the 34 trials are tagged with Proximal Femoral Fractures itself; the rest are tagged with a narrower condition beneath it.
When did Proximal Femoral Fractures trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 6 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 3 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 4 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Proximal Femoral Fractures trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 4 | 1 |
| Not applicable | 19 |
| Observational | 13 |
How many Proximal Femoral Fractures trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 18 |
| Terminated | 3 |
| Unknown status | 10 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Proximal Femoral Fractures trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AgNovos Healthcare, LLC | 1 |
| DePuy Orthopaedics | 1 |
| Fondation Ophtalmologique Adolphe de Rothschild | 1 |
Which drugs are being tested for Proximal Femoral Fractures? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| COVID-19 | 1 |
| +/- Bupivacaine HCl | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Femoral Nerve Block | 2 |
| Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms) | 1 |
| Spinal Anesthesia | 1 |
| Pericapsular Nerve Group (PENG) Block | 1 |
| Fascia Iliaca Nerve Block | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Proximal Femoral Fractures trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Bone fracture acetabulum | 1 | 1 |
| Cancer | 1 | 1 |
| Death | 1 | 1 |
| Foot numbness | 1 | 1 |
| Implant removal | 1 | 1 |
Which publications cover Proximal Femoral Fractures? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.